Product Description
ADG152 is a novel CD20xCD3 TCE prodrug engineered using Adagene's SAFEbody technology to minimize or eliminate CRS and on-target/off-tumor toxicities. (Sourced from: https://ashpublications.org/blood/article/138/Supplement%201/1204/480432)
Mechanisms of Action: CD20 Antagonist,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adagene
Company Location: JIANGSU F4 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|